New pill aims to turn off Cancer's growth switch
NCT ID NCT02423057
Summary
This early-stage study tested a new oral drug called TdCyd in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see how the drug works in the body. Researchers hoped the drug might slow tumor growth by reactivating certain genes that help control cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.